Physician

Hematology

Dr. Heidi H. Gillenwater, MD

Heidi Gillenwater practices Hematology. He attended University of Washington School of Medicine. Heidi H. Gillenwater is also a published doctor. He has 19 paper published. The most recent paper is: Phase I trial of induction histone deacetylase and proteasome inhibition followed by surgery in non-small-cell lung cancer.

Publications

Phase I trial of induction histone deacetylase and proteasome inhibition followed by surgery in non-small-cell lung cancer.
A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or ...
Phase I trial of intrapleural docetaxel administered through an implantable catheter in subjects with a malignant pleural effusion.
Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Thera...
Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer.
Second-line treatment of small-cell lung cancer.
Phase II study of BBR 3464 as treatment in patients with sensitive or refractory small cell lung cancer.
A phase I/II trial of weekly docetaxel and gefitinib in elderly patients with stage IIIB/IV non-small cell lung cancer.
A phase II trial of weekly paclitaxel and gemctiabine infused at a constant rate in patients with advanced non-small cell lung cancer.
A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer.
Treatment options for small cell lung cancer.
Gemcitabine pharmacokinetics and interaction with paclitaxel in patients with advanced non-small-cell lung cancer.
Phase II trial of irinotecan, paclitaxel and carboplatin in patients with previously untreated Stage IIIB/IV nonsmall cell lung carcinoma.
Phase II evaluation of amifostine as an esophageal mucosal protectant in the treatment of limited-stage small cell lung cancer with chemotherapy and twice-daily radiat...
Measured versus estimated glomerular filtration rate in the Calvert equation: influence on carboplatin dosing.
Second-line gemcitabine in refractory stage IV non small-cell lung cancer: a phase II trial.
In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone.
Second-line chemotherapy with 96-hour infusional paclitaxel in refractory non-small cell lung cancer: report of a phase II trial.

Schools

University of Washington

Doctors Specialties

Medical Oncology
Oncology
Hematology

Accepted Insurances

Choice Care PPO
PHCS Network PPO

Education

University of North Carolina Hospitals
University of Washington School of Medicine

Helpful Reviews

Give Anonymous Review

Similar Doctors

	Dr. Michael G. Douvas, MD This Doctor is OpenDoctor Recommended.
	Dr. Paula M. Fracasso, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Thomas P. Loughran, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Maya Ghaemmaghami, MD This Doctor is OpenDoctor Recommended.
	Dr. Tamila Kindwall-Keller, MD This Doctor is OpenDoctor Recommended.
	Aarti Ailawadi, PA